In vitro data demonstratedself-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 ...
This article and associated images are based on a poster originally authored by Marina Fedorova and Ian Hiles and presented at ELRIG Drug Discovery 2024 in affiliation with GSK. This poster is being ...
Scientists at the VIB–VUB Center for Structural Biology have uncovered a counterintuitive principle that could reshape how ...
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...
This article is based on a poster originally authored by Sunidhi Shetty, Narasimha Murthy Bandaru, Anna Moberg and Marco Manni, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results